SLCTR_2020_024
A long-term clinical study using Evenamide (orally taken new drug without masking its strength) to determine its safety, tolerability and efficacy in patients with treatment resistant schizophrenia, not befitting adequately from their current antipsychotic medication
An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication
Dr Ravi Anand/Newron Pharmaceuticals S.p.A·Phase 2·Sri Lanka Clinical Trials RegistryRecruiting
Study focus
- Disease/Condition
- Schizophrenia
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Dr Ravi Anand/Newron Pharmaceuticals S.p.A
- Location
- India, Italy, Malaysia, Sri Lanka
Timeline & enrollment
- Phase
- Phase 2
- Start date
- May 03, 2021
- End date
- N/A
ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
- Registry
- Sri Lanka Clinical Trials Registry
- Trial ID
- SLCTR_2020_024
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for SLCTR_2020_024 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dr Ravi Anand/Newron Pharmaceuticals S.p.A and is currently Recruiting. The study focuses on Schizophrenia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.